Trimetazidine Instable angina pectoris and Type 2 Diabetes Mellitus: Safety & Effectiveness: A Descriptive study

An observational, non interventional, open-label clinical study assessed the effectiveness/safety of trimetazidine in 101 patients with stable angina pectoris and Type 2 diabetes mellitus. Results: Trimetazidine-based therapy was effective in stable coronary artery disease, with significant improvements from baseline (p < 0.05) in: number of angina attacks/week (2.9 2.4 vs 1.1 1.6), angina severity (Canadian Cardiovascular Society Classification 1.9 0.8 vs 1.2 0.8), exercise capacity (metabolic equivalents 6.8 1.7 vs 6.5 1.7), and exercise-induced myocardial ischemia (min 5.5 2.5 vs 6.5 2.6). Discussion: Trimetazidine treatment significantly (p < 0.05) improved glucose metabolism, lowered HbA1c (7.1 1.1% vs 6.6 1.0%), glucose levels (7.7 2.1 mmol/l vs 6.9 1.6 mmol/l) and decreased arterial stiffness (pulse wave velocity 11.2 2.1 m/s vs 10.4 2.2 m/s). In most patients, the tolerability of trimetazidine was rated as excellent to good, with a low incidence of adverse events.